Your Health, We Care
The table below lists the potential effects of strong CYP3A modulators on idelalisib.
Clinical Impact: Concomitant use with strong CYP3A inhibitors may increase idelalisib concentrations. Increased idelalisib concentrations may raise the risk of exposure-related adverse reactions.
Prevention or Management: Use alternative medications that are not strong CYP3A inhibitors. If alternative drugs are unavailable, monitor patients more frequently for idelalisib-related adverse reactions.
Clinical Impact: Concomitant use with strong CYP3A inducers may decrease idelalisib concentrations. Decreased idelalisib concentrations may reduce efficacy.
Prevention or Management: Avoid concomitant use of idelalisib with strong CYP3A inducers.
Concomitant use of idelalisib with CYP3A substrates may increase the concentrations of such CYP3A substrates. Avoid concomitant use of idelalisib with sensitive CYP3A substrates.
FDA，2022.02
